Log in to search using one of your social media accounts:

 

Payment delays by NACO causing HIV drugs scarcity
Cipla, the sole producer of lopinavir/ritonavir, a combination HIV drug prescribed for paediatric patients, has stopped manufacturing it over non-clearance of arrears by NACO. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 6, 2017 Category: Pharmaceuticals Source Type: news

Kaletra Capsules (Lopinavir, Ritonavir Capsules) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 8, 2016 Category: Drugs & Pharmacology Source Type: news

Improvement of Lipoatrophy by Switching From EFV to LPV/r Improvement of Lipoatrophy by Switching From EFV to LPV/r
Switching HIV patients with lipoatrophy from efavirenz to lopinavir/ritonavir may affect positive changes in limb fat.HIV Medicine (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - September 20, 2016 Category: Infectious Diseases Tags: HIV/AIDS Journal Article Source Type: news

Interaction Between EE2/DSG and LPV/r in HIV+ Adolescents Interaction Between EE2/DSG and LPV/r in HIV+ Adolescents
Could oral contraceptives containing ethinyl estradiol/desogestrel compromise the effectiveness of lopinavir/ritonavir-based therapy?JAIDS: Journal of Acquired Immune Deficiency Syndromes (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - August 24, 2016 Category: Infectious Diseases Tags: HIV/AIDS Journal Article Source Type: news

Comunicado de la FDA sobre la seguridad de los medicamentos: Importantes interacciones entre el medicamento Victrelis (boceprevir) y los medicamentos inhibidores de la proteasa del virus de inmunodeficiencia humana (VIH) reforzados con ritonavir
El 8 de febrero del 2012, la Administración de Alimentos y Medicamentos de Estados Unidos (FDA por sus siglas en inglés) notificó a los profesionales de la salud y a los pacientes que la interacción entre Victrelis (boceprevir), un medicamento inhibidor de la proteasa del virus de hepatitis C (VHC), y ciertos inhibidores de la proteasa del virus de inmunodeficiencia humana (VIH) reforzados con ritonavir (atazanavir, lopinavir, darunavir) tiene el potencial de reducir la eficacia de dichos medicamentos cuando se usan conjuntamente (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 4, 2016 Category: Drugs & Pharmacology Source Type: news

Efavirenz linked with higher bone mass in children with HIV
BOSTON – Switching HIV-infected South African children from ritonavir-boosted lopinavir (LPV/r) to efavirenz (EFV)-based antiretroviral therapy improved bone mineral content in the children, compared... (Source: Pediatric News)
Source: Pediatric News - February 25, 2016 Category: Journals (General) Source Type: news

South Africa: Aids Day Highlights Need to Fix Patents Law
[News24Wire] The country's patent law is yet again under the microscope in light of World Aids Day and following the recent shortage of HIV medicine Lopinavir/Ritonavir (LPV/r), which is a life-line for nearly 10% of the country's approximately 3 million people on HIV treatment. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - December 1, 2015 Category: African Health Source Type: news

CHMP Backs Generic Lopinavir/Ritonavir Mylan for HIVCHMP Backs Generic Lopinavir/Ritonavir Mylan for HIV
Studies demonstrate the satisfactory quality of Lopinavir/Ritonavir Mylan and its bioequivalence to the reference product Kaletra, the committee said. International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 20, 2015 Category: Consumer Health News Tags: HIV/AIDS News Alert Source Type: news

Switch to Efavirenz-based ART Effective Option in KidsSwitch to Efavirenz-based ART Effective Option in Kids
A new study has found that switching to efavirenz-based ART vs continuing on ritonavir-boosted lopinavir-based ART was not tied to higher rates of viral rebound and failure in children. Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - November 5, 2015 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

South Africa Should Override Patent on Key HIV Medicine After Widespread Stock Out Problem
Press releaseSouth Africa Should Override Patent on Key HIV Medicine After Widespread Stock Out Problem October 28, 2015 JOHANNESBURG—After six months of persistent supply problems with the key HIV medicine lopinavir/ritonavir (LPV/r), the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) urged the South African government to put the public’s health first and override pharmaceutical company AbbVie’s patent with a "compulsory licence," in order to allow generic versions of LPV/r to be used in the country. (Source: MSF News)
Source: MSF News - October 28, 2015 Category: Global & Universal Authors: Elias Primoff Source Type: news

South Africa: Red Flag Over HIV Medicine Stock Out
[News24Wire] Doctors Without Borders wants the South African government to issue a landmark compulsory license to allow generic manufacturers to come to the aid of thousands of HIV patients in need of Lopinavir/Ritonavir (LPV/r). (Source: AllAfrica News: HIV-Aids and STDs)
Source: AllAfrica News: HIV-Aids and STDs - October 28, 2015 Category: Infectious Diseases Source Type: news

There May Have Been a Major Breakthrough in MERS Treatment
Two existing and widely available drugs may prove to be effective treatments for Middle East Respiratory Syndrome (MERS), new research published by the University of Hong Kong suggests. According to the South China Morning Post, the medicines—lopinavir with ritonavir and a type of interferon—were tested on marmosets, small monkeys that a 2014 U.S. study concluded would be the best subject for MERS trials because of the way their reactions to the virus mimics human illness. The drugs, currently used to treat HIV and sclerosis, were found to be effective in curing MERS-infected marmosets. The research is the firs...
Source: TIME.com: Top Science and Health Stories - July 28, 2015 Category: Consumer Health News Authors: alissagreenberg Tags: Uncategorized Hong Kong medicine MERS monkeys Science South Korea Source Type: news

lopinavir and ritonavir, Kaletra
Title: lopinavir and ritonavir, KaletraCategory: MedicationsCreated: 3/12/2001 12:00:00 AMLast Editorial Review: 7/9/2015 12:00:00 AM (Source: MedicineNet HIV General)
Source: MedicineNet HIV General - July 9, 2015 Category: Infectious Diseases Source Type: news

FDA Updates Kaletra Labeling
"The Kaletra (lopinavir/ritonavir) product labeling was updated to include drug-drug interaction information with etravirine, rilpivirine and simeprevir and to update the Use in Specific Populations, Pediatric Use subsection with information from a clinical trial that investigated the use of a once daily dosing regimen."   The updated labeling will be available soon at the FDA website.   More information is available: FDA: Press release AIDSinfo: Patient fact sheet on Kaletra (Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. D...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - July 2, 2015 Category: Infectious Diseases Source Type: news

FDA Approves First Pediatric Lopinavir/Ritonavir Oral Pellets for the Treatment of AIDS in Infants and Young Children
Mumbai, India - June 3, 2015 --Cipla Limited, a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients, today announced that it has received US FDA approval for an innovative... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 3, 2015 Category: Pharmaceuticals Source Type: news

Cipla gets USFDA nod for Lopinavir, Ritonavir oral pellets
Cipla has received approval from US health regulator USFDA for Lopinavir and Ritonavir oral pellets used for treating AIDS in infants and young children. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 3, 2015 Category: Pharmaceuticals Source Type: news

Antiretrovirals Linked to Cumulative Kidney RiskAntiretrovirals Linked to Cumulative Kidney Risk
The chance of developing chronic kidney disease increases steadily in patients taking tenofovir, ritonavir-boosted atazanavir, or ritonavir-enhanced lopinavir, researchers warn. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 27, 2015 Category: Consumer Health News Tags: HIV/AIDS News Source Type: news

FDA Approves Changes to Kaletra Label
"On January 28, [2015] FDA approved changes to the Kaletra (lopinavir/ritonavir) label to include dosing recommendations in pregnant women."   More information is available: FDA: Press release AIDSinfo: Patient fact sheet on Kaletra (Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS))
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - January 30, 2015 Category: Infectious Diseases Source Type: news

FDA Updates Etravirine Labeling
"On August 20, 2014, the Intelence (etravirine) label was updated to include information regarding coadministration of etravirine with the following drugs: "dolutegravir, dolutegravir/darunavir/ritonavir, dolutegravir/lopinavir/ritonavir "atazanavir/ritonavir "boceprevir" The updated labeling for etravirine is available at the FDA website. More information is available: FDA: Press release AIDSinfo: Patient fact sheet on etravirine (Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS))
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - August 29, 2014 Category: Infectious Diseases Source Type: news

Dual Therapy Effective in Newly Diagnosed HIV-1 InfectionDual Therapy Effective in Newly Diagnosed HIV-1 Infection
In previously untreated adults with HIV-1 infection, dual therapy with lopinavir and ritonavir plus lamivudine is as effective as triple therapy with lopinavir and ritonavir plus two NRTIs. Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - May 12, 2014 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

Uganda: HIV Drugs Could Treat Cervical Cancer - Study
[Observer]A commonly used oral combination HIV drug of lopinavir and ritonavir could be taken as a vaginal capsule to kill the virus that leads to cervical cancer in women, a phase I clinical trial in Kenya reveals. Cervical cancer is caused by the uncontrolled growth of some cells on the cervix (the organ connecting the uterus to the vagina). Cells on the cervix begin to grow slowly and abnormally over several years. (Source: AllAfrica News: HIV-Aids and STDs)
Source: AllAfrica News: HIV-Aids and STDs - April 30, 2014 Category: Infectious Diseases Source Type: news

Could a Commonly Prescribed HIV Drug Prevent Cervical Cancer?
We have to admit we were somewhat startled last week by news that lopinavir, the key agent in the HIV protease inhibitor-class drug Kaletra, is apparently able to wipe out pre-cancerous cells associated with the development of cervical cancer....Read Full Post (Source: About AIDS / HIV)
Source: About AIDS / HIV - February 24, 2014 Category: Consumer Health News Source Type: news

[Press Release] Proposed Shake-up on Drug-Pricing at Global Fund Risks Higher Costs for Middle Income Countries and Donors
Myanmar 2012 © Sami Siva A patient shows a daily dose of his medication for extensively drug-resistant tuberculosis GENEVA/NEW YORK, DECEMBER 2, 2013—Ahead of the Global Fund replenishment conference in Washington, DC, this week, the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) has warned the Global Fund to Fight AIDS, Tuberculosis, and Malaria of the consequences of spearheading a new pricing initiative that could result in middle-income countries paying significantly higher prices for medicines to combat diseases including HIV and t...
Source: MSF News - December 3, 2013 Category: Global & Universal Source Type: news

Proposed shake-up to drug pricing framework risks middle-income countries paying more
International medical humanitarian organization Médecins Sans Frontières (MSF) has warned the Global Fund to Fight AIDS, Tuberculosis and Malaria of the consequences of a new pricing initiative that could result in middle-income countries paying significantly higher prices for medicines to combat diseases including HIV and tuberculosis. The warning comes ahead of the Global Fund replenishment conference in Washington, DC, this week. “MSF programs are already seeing how middle-income countries like Ukraine, Honduras, or Thailand pay exorbitant prices for drugs and vaccines because of the tiered pricing ...
Source: MSF News - December 2, 2013 Category: Global & Universal Tags: Access Campaign NEWS Frontpage Generic Drugs HIV / AIDS Source Type: news

Proposed Shake-up on Drug-Pricing at Global Fund Risks Higher Costs for Middle Income Countries and Donors
Myanmar 2012 © Sami Siva A patient shows a daily dose of his medication for extensively drug-resistant tuberculosis GENEVA/NEW YORK, DECEMBER 2, 2013—Ahead of the Global Fund replenishment conference in Washington, DC, this week, the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) has warned the Global Fund to Fight AIDS, Tuberculosis, and Malaria of the consequences of spearheading a new pricing initiative that could result in middle-income countries paying significantly higher prices for medicines to combat diseases including HIV and t...
Source: MSF News - December 2, 2013 Category: Global & Universal Source Type: news

Low-Dose Drug Combo Safe in Kids with HIV (CME/CE)
KUALA LUMPUR (MedPage Today) -- A low-dose treatment regimen with lopinavir/ritonavir antiretroviral therapy appears to have similar efficacy with fewer adverse events than standard dosing in HIV-infected children, researchers said here. (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - July 5, 2013 Category: Consumer Health News Source Type: news

HIV Drug Not Tied to Premature Births (CME/CE)
ATLANTA (MedPage Today) -- Pregnant HIV-infected women treated with a lopinavir/ritonavir (Kaletra)-based antiretroviral regimen are at no greater risk of delivering a preterm baby than those given an efavirenz (Sustiva)-based treatment, researchers said. (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - March 8, 2013 Category: Consumer Health News Source Type: news

Generics in Global Antivirals Market Forecast to Reach $9.2 Billion by...
Research and Markets Announces the Addition of GBI's Research "Generics in the Antivirals Market to 2018 - Launch of Generic Combivir and Patent Expiry of Sustiva, Kaletra and Epivir-HBV will...(PRWeb February 14, 2013)Read the full story at http://www.prweb.com/releases/2013/2/prweb10433563.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 15, 2013 Category: Pharmaceuticals Source Type: news

HIV/AIDS Update - Kaletra (lopinavir/ritonavir) label update: drug interaction information
On January 17, 2013, FDA approved revisions to the Kaletra (lopinavir/ritonavir) labels to include new drug interaction information. The following updates were included. Anticoagulants: Rivaroxaban. Avoid concomitant use of rivaroxaban and Kaletra.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 23, 2013 Category: Pharmaceuticals Source Type: news

FDA Updates Lopinavir/Ritonavir (Kaletra) Labeling to Include New Drug Interaction Information
"On January 17, 2013, FDA approved revisions to the Kaletra (lopinavir/ritonavir) labels to include new drug interaction information. The following updates were included. "Anticoagulants: Rivaroxaban. Avoid concomitant use of rivaroxaban and Kaletra. Coadministration of Kaletra and rivaroxaban is expected to result in increased exposure of rivaroxaban which may led to risk of increased bleeding "Anticonvulsants: Lamotrigine and valproate. Coadministration of Kaletra and lamotrigine or valproate may decrease the exposure of lamotrigine or valproate. A dose increase of the lamotrigine or valproate may be nee...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - January 22, 2013 Category: Infectious Diseases Source Type: news

Long-term Results With DRV/r vs LPV/rLong-term Results With DRV/r vs LPV/r
How does once-daily darunavir/ritonavir compare with lopinavir/ritonavir in HIV-1-infected treatment-naive patients? HIV Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 7, 2013 Category: Consumer Health News Tags: HIV/AIDS Journal Article Source Type: news